The Charterhouse Rheumatism Charity and ongoing research into rheumatology and musculoskeletal medicine.
The Charterhouse Rheumatism Charity (the Charity) was established in 1936 to continue the work of the Charterhouse Rheumatism Clinic.
New Lancet Rheumatology paper shows low risk of severe outcomes from Rituximab use for patients who receive COVID and Booster vaccination
Patients taking an immunosuppressant drug for rheumatic and musculoskeletal diseases do not appear to be at higher risk of serious outcomes from COVID-19 infection as long as they are vaccinated.
New research has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
Medical record linkage study discovers that patients receiving low dose steroid are at an increased risk of cardiovascular disease
Medication used to treat a range of inflammatory diseases may be less safe than previously thought.
Drugs used to treat initial signs of rheumatoid arthritis also improve the early stages of heart disease, according to new research.